A tier · strong
Isotretinoin is the most effective treatment available for severe recalcitrant nodular acne with decades of clinical use and regulatory backing, but the randomised literature comparing regimens is graded moderate to low quality, and its risk profile is severe enough to require a national restricted-distribution programme.
isotretinoin
Isotretinoin is an oral retinoid approved for severe recalcitrant nodular acne unresponsive to conventional therapy including systemic antibiotics. It is highly effective and highly teratogenic, and in the United States can only be prescribed and dispensed through the iPLEDGE restricted distribution programme.
the explanation
Isotretinoin is the strongest acne treatment there is, and for severe scarring acne it often produces lasting clearance. It also causes severe birth defects, so in the US it can only be obtained through a strict monitoring programme with mandatory pregnancy testing.
regulatory status
FDA-approved under restricted distribution (iPLEDGE REMS)
Approved for severe recalcitrant nodular acne unresponsive to conventional therapy including systemic antibiotics, in patients meeting all iPLEDGE requirements. Prescribers, pharmacies and patients must all be registered. Carries a boxed warning on teratogenicity.
how it works · proposed mechanism
Isotretinoin acts through nuclear retinoid receptors to reprogram sebaceous gland and follicular biology.
Sebaceous gland suppression
Retinoid receptor signalling induces sebocyte apoptosis and shrinks sebaceous glands, sharply reducing sebum production. This removes the substrate on which acne pathogenesis depends and is why the effect often outlasts treatment.
Follicular normalisation
Isotretinoin normalises abnormal keratinisation within the pilosebaceous unit, reducing comedone formation. The reduced sebum and altered follicular environment together lower Cutibacterium acnes colonisation without direct antibiotic action.
Embryonic retinoid signalling
Retinoic acid receptors govern anterior-posterior patterning and neural crest migration in the developing embryo. Exogenous retinoid exposure disrupts this, producing the characteristic craniofacial, cardiac, thymic and CNS malformation syndrome described on the label.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Isotretinoin's A grade is for severe recalcitrant nodular acne under monthly medical supervision with mandatory pregnancy testing and registered dispensing — the evidence and the risk management are inseparable, and neither transfers to casual cosmetic use for mild acne or skin texture bought outside that system. Obtaining isotretinoin outside iPLEDGE removes the pregnancy testing, contraception verification and laboratory monitoring that the entire benefit-risk case for this drug is built on.
key published findings
- Regulatory (boxed warning): the label states 'CAUSES BIRTH DEFECTS, DO NOT GET PREGNANT' and that isotretinoin 'must not be used by female patients who are or may become pregnant.'
- Regulatory (label, malformation syndrome): documented defects include skull abnormalities, ear abnormalities (anotia, micropinna), microphthalmia, facial dysmorphia, cleft palate, cerebral and cerebellar malformation, hydrocephalus, microcephaly, cranial nerve deficits, cardiovascular abnormalities, thymic abnormality and parathyroid hormone deficiency, plus reported IQ scores below 85 and spontaneous abortion.
- Human observational (meta-analysis): Tan and colleagues in JAMA Dermatology found isotretinoin was 'not associated with the risk of all psychiatric disorders' (RR 1.08; 95% CI 0.99-1.19), with 1-year absolute risk of depression 3.83% (95% CI 2.45-5.93) and suicide attempt, ideation and self-harm each under 0.5% at 1 year.
- Human observational (same meta-analysis): isotretinoin users showed lower suicide attempt risk than nonusers at 2 years (RR 0.92), 3 years (RR 0.86) and 4 years (RR 0.85), consistent with treatment of severe acne reducing rather than increasing psychiatric burden.
- Human observational (meta-analysis with trial sequential analysis): Yu and colleagues found no significant association between isotretinoin and inflammatory bowel disease overall (OR 1.01; 95% CI 0.80-1.27), Crohn disease (OR 0.87; 95% CI 0.65-1.15) or ulcerative colitis (OR 1.27; 95% CI 0.94-1.73).
- Human trial (systematic review and meta-analysis): Al Muqarrab and Almohssen found conventional-dose regimens improved the odds of prolonged remission compared with low-dose regimens, and outperformed pulsed regimens, but rated the quality of evidence moderate to low by GRADE.
limitations of the evidence
- The randomised literature comparing regimens is rated moderate to low quality by GRADE, so the optimal treatment strategy rests on weaker evidence than the drug's overall efficacy does.
- Psychiatric and IBD safety evidence is observational and subject to confounding by indication — severe acne itself is associated with anxiety, depression and suicidal ideation, which complicates attributing outcomes to the drug.
- Much of the foundational efficacy evidence predates modern trial reporting standards, and long-term relapse data come largely from cohort rather than randomised follow-up.
documented safety signals
- BOXED WARNING: extreme teratogenicity. Exposure during pregnancy causes a well-characterised syndrome of craniofacial, cardiovascular, thymic and central nervous system malformations, and is associated with spontaneous abortion and with IQ scores below 85 in exposed children.
- iPLEDGE REMS requirements in the US: registration of prescribers, pharmacies and patients; two negative pregnancy tests before starting; two simultaneous forms of effective contraception from one month before through one month after treatment; monthly pregnancy testing; and monthly educational requirements.
- Psychiatric: the label states isotretinoin 'may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive and/or violent behaviors,' with instructions to discontinue and contact the prescriber. Meta-analysis has not found an increased population-level risk (RR 1.08; 95% CI 0.99-1.19), but the individual-level label warning stands.
- Hepatic: elevated transaminases occur and require laboratory monitoring; hepatitis has been reported.
- Lipids: marked hypertriglyceridaemia is common and can precipitate acute pancreatitis; lipid monitoring is required.
- Ocular: decreased night vision, which may be sudden in onset and may persist after discontinuation; corneal opacities; dry eye and intolerance of contact lenses.
- Intracranial hypertension (pseudotumor cerebri), with markedly increased risk when combined with tetracyclines — a combination that is contraindicated.
- Musculoskeletal: myalgia, arthralgia, elevated CPK, and with prolonged exposure premature epiphyseal closure, hyperostosis and decreased bone mineral density.
- Mucocutaneous: severe cheilitis, xerosis, epistaxis, photosensitivity, and acne flare early in treatment.
- Severe skin reactions including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
- Blood donation is prohibited during treatment and for one month afterwards to prevent transfusion exposure of a pregnant recipient.
- Contraindicated with tetracycline antibiotics; vitamin A supplementation adds additive retinoid toxicity.
- Obtaining isotretinoin outside iPLEDGE removes the mandatory pregnancy testing, contraception verification and laboratory monitoring that constitute the drug's entire risk-management framework.
identity
| full name | Isotretinoin (13-cis-retinoic acid) |
| category | Cosmetic |
| modality | small molecule |
| formula | C20H28O2 |
| molar mass | 300.4 g/mol |
| cas | 4759-48-2 |
| half-life | ~21 h (mean elimination) |
laboratory handling
| storage | Marketed capsules are stored at controlled room temperature, protected from light, in a tight light-resistant container per the approved label; isotretinoin is light-sensitive and oxidises on air exposure. |
| solubility | Isotretinoin is practically insoluble in water and lipophilic, which is why marketed capsules are lipid-based formulations and why absorption is substantially food-dependent for conventional products. |
| co-studied with | Documented hazards rather than a regimen: concomitant tetracyclines are contraindicated because of additive intracranial hypertension risk; vitamin A and other retinoids produce additive retinoid toxicity; alcohol compounds the hypertriglyceridaemia and hepatic signals; and micro-dosed progestin-only oral contraceptives are not considered adequate contraception under the label. These are the interactions the REMS monitoring is designed to catch. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedUS FDA Drugs@FDA · 2008 · official
US FDA Drugs@FDA · 2012 · official
iPLEDGE REMS (US FDA-mandated programme) · 2023 · official
JAMA Dermatology · 2024 · observational
American Journal of Clinical Dermatology · 2023 · observational
Dermatologic Therapy · 2022 · randomized
others in Cosmetic